Fallopian Tube Cancer - Pipeline Review, H1 2012
Global Markets Direct
January 23, 2012 150 Pages - SKU: GMD6775868
|
|
Fallopian Tube Cancer - Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Fallopian Tube Cancer - Pipeline Review, H1 2012', provides an overview of the Fallopian Tube Cancer therapeutic pipeline. This report provides information on the therapeutic development for Fallopian Tube Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer. 'Fallopian Tube Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Fallopian Tube Cancer.
- A review of the Fallopian Tube Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Fallopian Tube Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Fallopian Tube Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Fallopian Tube Cancer pipeline depth and focus of Fallopian Tube Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
|
- Introduction
- Global Markets Direct Report Coverage
- Fallopian Tube Cancer Overview
- Therapeutics Development
- An Overview of Pipeline Products for Fallopian Tube Cancer
- Fallopian Tube Cancer Therapeutics under Development by Companies
- Fallopian Tube Cancer Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Fallopian Tube Cancer Therapeutics - Products under Development by Companies
- Fallopian Tube Cancer Therapeutics - Products under Investigation by Universities/Institutes
- Companies Involved in Fallopian Tube Cancer Therapeutics Development
- Boehringer Ingelheim GmbH
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Amgen Inc.
- Sanofi-Aventis
- Eli Lilly and Company
- Takeda Pharmaceutical Company Limited
- Millennium Pharmaceuticals, Inc.
- Novartis AG
- ImClone Systems Incorporated
- Cell Therapeutics, Inc.
- EntreMed, Inc.
- Novogen Limited
- Oncolytics Biotech Inc.
- TopoTarget A/S
- Synta Pharmaceuticals Corp.
- Oasmia Pharmaceutical AB
- MabVax Therapeutics, Inc.
- BiPar Sciences, Inc.
- ImmunoVaccine Technologies Inc.
- TRACON Pharmaceuticals, Inc.
- RECEPTA Biopharma S.A.
- Fallopian Tube Cancer - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- AMG 386 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- OPAXIO - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Paclical - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Phenoxodiol + Carboplatin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Bevacizumab + Carboplatin + Gemcitabine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Carboplatin + Paclitaxel + Bevacizumab - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Carboplatin + Paclitaxel + Bevacizumab - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Oxaliplatin + Capecitabine + Bevacizumab - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Carboplatin + Gemcitabine + Paclitaxel - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Carboplatin + Paclitaxel - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Carboplatin + Ifosfamide - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Carboplatin + Ifosfamide + Whole Body Hyperthermia - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Carboplatin + Paclitaxel + Cediranib - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Carboplatin + Paclitaxel - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Carboplatin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Bevacizumab + Carboplatin + Docetaxel + Paclitaxel - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Paclitaxel - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Taxol + Paraplatin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- AMG 386 + Pegylated Liposomal Doxorubicin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- AMG 386 + Paclitaxel - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Carboplatin + Gemcitabine Hydrochloride + Paclitaxel - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Avastin + Carboplatin + Paclitaxel - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Avastin + Carboplatin + Paclitaxel - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Avastin + Paclitaxel + Topotecan + Liposomal Doxorubicin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Bevacizumab + Cisplatin + Paclitaxel - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Cisplatin + Carboplatin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Taxol + Paraplatin + Bevacizumab - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Paclitaxel + Carboplatin + Epirubicin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Paclitaxel + AZD0530 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Bevacizumab + Carboplatin + Paclitaxel - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- OPT-821 + Polyvalent Antigen-KLH Conjugate Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Cisplatin + Topotecan + Paclitaxel + Carboplatin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Carboplatin + Glutathione + Paclitaxel - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- bevacizumab + capecitabine + carboplatin + oxaliplatin + paclitaxel - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Carboplatin + Paclitaxel + Bevacizumab - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Cisplatin + Paclitaxel - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- CT-2103 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Fallopian Tube Cancer Therapeutics - Drug Profile Updates
- Fallopian Tube Cancer Therapeutics - Discontinued Products
- Fallopian Tube Cancer Therapeutics - Dormant Products
- Fallopian Tube Cancer - Product Development Milestones
- Featured News & Press Releases
- Nov 01, 2010: Synta Announces Gynecologic Oncology Group To Initiate Phase II Clinical Trial Of Elesclomol For Treatment Of Ovarian Cancer
- Nov 01, 2010: Synta Announces Gynecologic Oncology Group To Initiate Phase II Clinical Trial Of Elesclomol For Treatment Of Ovarian Cancer
- Sep 02, 2010: Oncolytics Biotech Announces Phase II Ovarian Cancer Study To Be Conducted By Gynecologic Oncology Group
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Fallopian Tube Cancer, H1 2012
- Products under Development for Fallopian Tube Cancer - Comparative Analysis, H1 2012
- Number of Products under Development by Companies, H1 2012
- Number of Products under Development by Companies, H1 2012 (Contd..1)
- Number of Products under Investigation by Universities/Institutes, H1 2012
- Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
- Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
- Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
- Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
- Comparative Analysis by Late Stage Development, H1 2012
- Comparative Analysis by Mid Clinical Stage Development, H1 2012
- Comparative Analysis by Early Clinical Stage Development, H1 2012
- Products under Development by Companies, H1 2012
- Products under Development by Companies, H1 2012 (Contd..1)
- Products under Development by Companies, H1 2012 (Contd..2)
- Products under Investigation by Universities/Institutes, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..6)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..7)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..8)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..9)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..10)
- Boehringer Ingelheim GmbH, H1 2012
- F. Hoffmann-La Roche Ltd., H1 2012
- Abbott Laboratories, H1 2012
- Amgen Inc., H1 2012
- Sanofi-Aventis, H1 2012
- Eli Lilly and Company, H1 2012
- Takeda Pharmaceutical Company Limited, H1 2012
- Millennium Pharmaceuticals, Inc., H1 2012
- Novartis AG, H1 2012
- ImClone Systems Incorporated, H1 2012
- Cell Therapeutics, Inc., H1 2012
- EntreMed, Inc., H1 2012
- Novogen Limited, H1 2012
- Oncolytics Biotech Inc., H1 2012
- TopoTarget A/S, H1 2012
- Synta Pharmaceuticals Corp., H1 2012
- Oasmia Pharmaceutical AB, H1 2012
- MabVax Therapeutics, Inc., H1 2012
- BiPar Sciences, Inc., H1 2012
- ImmunoVaccine Technologies Inc., H1 2012
- TRACON Pharmaceuticals, Inc., H1 2012
- RECEPTA Biopharma S.A., H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Combination Products, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Fallopian Tube Cancer Therapeutics - Drug Profile Updates
- Fallopian Tube Cancer Therapeutics - Discontinued Products
- Fallopian Tube Cancer Therapeutics - Discontinued Products (Contd..1)
- Fallopian Tube Cancer Therapeutics - Dormant Products
- Fallopian Tube Cancer Therapeutics - Dormant Products (Contd..1)
- Fallopian Tube Cancer Therapeutics - Dormant Products (Contd..2)
- Fallopian Tube Cancer Therapeutics - Dormant Products (Contd..3)
- List of Figures
- Number of Products under Development for Fallopian Tube Cancer, H1 2012
- Products under Development for Fallopian Tube Cancer - Comparative Analysis, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Late Stage Products, H1 2012
- Mid Clinical Stage Products, H1 2012
- Early Clinical Stage Products, H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Combination Products, H1 2012
- Assessment by Route of Administration, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Assessment by Stage and Molecule Type, H1 2012
Share this report
Other tasks Related Markets Obstetrics/Gynecology Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
